United States: House Subcommittee Circulates Proposed Legislation Providing Insight On The Future Of The 340B Drug Pricing Program

The 340B Federal Drug Pricing Program (the 340B Program) requires pharmaceutical manufacturers to offer drugs at discounted prices to eligible hospitals, clinics and other entities for use in the outpatient setting. The 340B Program was created by the Veterans Health Care Act of 1992 (codified at Section 340B of the Public Health Services Act) and is administered by the Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA), Office of Pharmacy Affairs (OPA). In recent years, attention to, and scrutiny of, the 340B Program has increased significantly, due in part to an expansion in the number of participating entities as a result of the Patient Protection and Affordable Care Act of 2010.

To participate in the 340B Program, entities must maintain full compliance with 340B Program requirements. Compliance with 340B Program requirements can be challenging, because guidance from OPA on a variety of significant topics has been unclear and subject to a range of interpretations, even in relation to fundamental questions of who may purchase and receive 340B drugs.

In 2014, OPA intended to release a 340B "Mega-Reg", a formal notice-and-comment rule intended to cover a broad swath of important compliance topics, including entity and patient eligibility. Prior to the issuance of the Mega-Reg, however, a United States federal district court, responding to litigation brought by the pharmaceutical manufacturers challenging the government's rulemaking authority in a related matter, issued a decision that called into question OPA's authority to issue regulations on such topics. (For further discussion of the case, see: Federal Court Vacates 340B Rule Regarding Orphan Drugs). OPA has since withdrawn the Mega-Reg and indicated that it will instead seek to issue omnibus guidance in 2015. As of May 2015, this guidance is under review at the Office of Management and Budget.

In light of increasing participation in the 340B Program and continued concerns regarding the lack of oversight and clarity regarding compliance with 340B Program requirements, the House Energy and Commerce Health Subcommittee (the Subcommittee) held a hearing pertaining to the 340B Program on March 24, 2015. While the hearing focused upon increased oversight and transparency in the 340B Program, the Subcommittee appeared open to revisiting the 340B statute to provide increased clarity and federal oversight of the 340B Program.

The recently released draft legislation would have made both cosmetic and material changes to the 340B Program, including, but not limited to

  • Renaming the 340B Program
  • Formally stating the purpose of the 340B Program
  • Refining the definition of a "patient" eligible to receive 340B drugs
  • Enhancing participating entities' data reporting requirements
  • Assessing a user fee on 340B purchases
  • Providing HHS with the authority to promulgate regulations governing many aspects of the 340B Program.

A section-by-section summary of the sections of the proposed legislation, with a focus on those provisions most relevant to health care providers participating in the 340B Program, follows below.

Summary of the Proposed Legislation

Section Title Summary Commentary
a Renaming Formally establishes the name for the 340B Program as the Outpatient Drug Discount Program. Although known commonly as the 340B Program, the program does not have a formal, statutorily established name. This provision would formally name the program the Outpatient Drug Discount Program.
b Purpose Sets forth the purpose of the 340B Program as to enable covered entities to utilize scarce resources to increase patient access to, and receipt of, health care services.

Explicitly states that the description of the intent of the 340B Program shall not be construed to limit dispensing of 340B drugs to individuals who are uninsured, underinsured, underserved or medically vulnerable.
The purpose of the 340B Program has been subject to much debate and disagreement between those who believe that it is intended to permit covered entities to expand access to health care services and those who believe it is intended to directly benefit eligible patients. There has also been debate as to whether 340B drugs are appropriately dispensed to all patients, or only to those who do not have third party pharmacy benefits.

This provision would clearly establish the intended purpose of the 340B Program and recipients of 340B drugs.
c Providing Ceiling Prices to State Medicaid Agencies Requires the Secretary of HHS to provide state Medicaid agencies with access to 340B ceiling price data. Explicitly states that the provision requiring access to ceiling prices shall not be construed to limit the covered entities' choice of which drug discounts or rebates to apply to drug purchases. This provision appears to provide state Medicaid agencies with the data necessary to enforce certain state Medicaid program requirements related to acquisition cost billing of 340B drugs.

It does not, however, impose federal restrictions on billing or charges for 340B drugs billed to state Medicaid agencies.
d Definition of Patient Codifies a definition of "patient" that is based on the current published definition of patient, with the addition of the requirements that the individual must have an in-person clinical/medical visit at the covered entity and that the individual receives a health care service that "results in" the ordering or prescribing of a covered outpatient drug. The proposed definition appears to address certain concerns regarding classifying as 340B-eligible patients certain individuals who have not received health care services from the covered entity, e.g., self-insured plan enrollees or employees. The proposed definition also appears to address concerns regarding the relationship between the care received at the covered entity and the prescription being filled with a 340B drug.
e Maintenance of Auditable Records Requires a covered entity to maintain auditable dispensing records for not less than five years. The requirement that covered entities maintain auditable records for at least five years formalizes a longer record retention period than the previously generally applied three year time period. The five year record retention period also potentially extends the look-back period for non-compliance.
no section number Limitation on Amount Charged to Uninsured Low-Income Patients Charges the Secretary of HHS to establish a methodology by which covered entities may collect fees for covered outpatient drugs dispensed to uninsured, low income patients. The Secretary of HHS would be able to set limits on how much a covered entity may charge for a 340B drug dispensed to an uninsured, low-income patient. This provision appears to be a response to concerns expressed in recent investigative reports that highlighted the fact that few covered entities provide discounts on 340B drugs dispensed to low income, uninsured patients through contract pharmacy arrangements, and concerns by patient advocacy and drug manufacturer groups that the benefits of 340B discounts are not being given directly to low income, uninsured patients.
no section number Interaction with Correctional Facilities Excludes correctional facilities, prisons, jails reformatories, detention centers, and similar facilities from eligibility as a covered entity. Prohibits covered entities from sharing or transferring revenue from the purchase or dispensing of a 340B drug to a correctional or similar facility. This provision appears to address historical concerns regarding arrangements between covered entities and correctional facilities to dispense 340B drugs to individuals residing in correctional facilities.

Concerns regarding the dispensing of 340B drugs at correctional facilities are not as widespread as they once were, and this provision appears to be intended to ensure that any such existing arrangements are discontinued.

f Treatment of Contract Pharmacy Services Governs contract pharmacy arrangements, requiring such agreements to be in writing and to be registered with the Secretary of HHS. The covered entity will also be required to ensure that the contract pharmacy arrangement and operations are compliant with 340B program requirements. A covered entity, in registering its contract pharmacy arrangement with HRSA, would need to report to HRSA the distance between the covered entity and the contract pharmacy.

Covered entities would need to conduct periodic audits of contract pharmacies and provide for independent annual audits.
g Manufacturer Requirements Requires manufacturers to maintain auditable records for not less than five years. The requirement that manufacturers maintain auditable records for at least five years facilitates audits and oversight by HRSA.
h Manufacturer Reporting of Sales Data Requires manufacturers to submit data on 340B drug sales to the Secretary of HHS on an annual basis. The sales data received from manufacturers will provide HRSA with additional information to use as a tool in its audit and oversight responsibilities.
i Independent Audit Required Requires that covered entities with 340B purchasing volumes in the top 10 per cent of all covered entities conduct an independent audit of 340B Program compliance and submit the results of the audit to HHS. There are currently no requirements for covered entities to conduct routine independent or internal audits of 340B Program compliance, although such reviews are strongly encouraged and increasingly becoming a common practice. The proposed language would result in certain entities being required to undertake such reviews and would appear to place less emphasis on entities in the bottom 90 per cent undertaking such reviews.

The provision would also require that covered entities subject to the audit requirement submit the results to HHS, which could result in compliance enforcement actions being taken by HHS in response to adverse findings by the independent auditor.
j Additional Penalties for Violations Expands existing interest penalties on covered entities for knowing and intentional drug diversion to instances of duplicate discounts. Revises the 340B Program removal penalty for "systemic and egregious" drug diversion to apply to "systemic, knowing and intentional drug diversion", and expands the penalty to duplicate discounts.

Establishes a removal penalty for systemic and routine violation of covered entity reporting requirements and a civil monetary penalty for intentional violation of covered entity reporting requirements.

Establishes a removal penalty for failure by a covered entity to take corrective action with respect to 340B Program violations in a "timely manner."
HHS has not historically applied the current covered entity penalty provisions and it is unclear if, and how, it would apply the proposed expanded provisions.
k Audits by Secretary Sets forth criteria to be used by the Secretary of HHS in determining which covered entities to audit. HHS prioritizes undertaking audits of those covered entities that have purchased a high volume of 340B drugs or have had compliance issues in the past.
l Reporting Requirements Establishes reporting requirements by covered entities of information related to the covered entity's patient population, 340B drug purchases and dispensing, payments received for 340B drugs, use of 340B revenue, prevention of duplicate discounts, provision of uncompensated care and 340B vendor arrangements. Critical Access Hospitals would be exempt from these reporting requirements. Information to be collected and reported under the proposed legislation is likely to be burdensome to collect and report. Several of the categories of information to be requested are not directly related to 340B Program eligibility or compliance requirements. It appears that much of the information to be collected could be used as the basis for future changes to the 340B Program, including establishing requirements for the use of 340B Program revenue, threshold uncompensated care volumes for participation, or reallocation of 340B Program savings between the covered entity and government payors.
m User Fees Establishes a fee that the Secretary of HHS will charge to covered entities for participation in the 340B Program. The amount of the fee will be determined using sales data, and will not exceed .1 per cent of each purchase of a 340B drug made by the covered entity during the previous year.

The fees will be used to cover the administrative and oversight costs to HRSA.
HRSA has not previously charged covered entities for participation in the 340B Program.
n Direct-Hire Authority For two years following the enactment of the legislation, the Secretary of HHS may directly hire up to 10 additional permanent employees to carry out management and oversight activities for the 340B Program. Allowing HHS to hire additional employees may expand HHS's audit and oversight capabilities, and could lead to an increased number, and/or an increased frequency, of audits.
o Technical and Conforming Amendments Makes certain technical and typographical changes to the existing statute.  
p Reports to Congress Requires the Secretary of HHS to submit a report to the Subcommittee on hospital covered entities. This report must include an analysis and description of options for replacing the DSH percentage as the qualifying factor for 340B eligibility.

Further requires the Comptroller General to submit a report to the Subcommittee on the use of contract pharmacies.
This provision illustrates the Subcommittee's ongoing concern with the participation by hospital covered entities in the 340B Program.
q Regulations Mandates that the Secretary of HHS issue proposed rulemakings within 180 days following the enactment of the legislation on certain 340B topics, including covered entity eligibility, definition of patient, contract pharmacy requirements and reporting requirements.

Requires the Secretary of HHS to promulgate regulations within two years on the following 340B topics: duplicate discounts; limits on amounts charged to low-income, uninsured patients; exclusion of correctional facilities; prohibition on revenue sharing with correctional facilities; penalties for certain violations; and user fees.
HRSA's current authority to issue formal notice-and-comment rules pertaining to the 340B Program was called into question by a 2014 federal district court case. HRSA's explicit statutory authority to promulgate rules for the 340B Program is narrow. This provision would therefore expand HRSA's rulemaking authority over a wide array of integral 340B topics that are expected to be covered in omnibus guidance to be issued by HRSA later this year.

This change would not, however, give HRSA the authority to define certain statutory provisions pertaining to "orphan drugs," which has been the subject of litigation between the pharmaceutical industry and the government.

House Subcommittee Circulates Proposed Legislation Providing Insight On The Future Of The 340B Drug Pricing Program

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Ostrow Reisin Berk & Abrams
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Ostrow Reisin Berk & Abrams
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions